Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
|Slideshows|May 5, 2017
The Nose Knows
Author(s)Mark L. Fuerst
The latest news in geriatric psychiatry covers olfactory deficits in cognitively impaired patients, a smartphone app for older adults with serious mental illness, and adjunctive ketamine for late-life depression.
Advertisement
Advertisement
Related to this article
Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
FDA grants Breakthrough Device status to NET Recovery’s tACS wearable, aiming to curb cocaine and meth use and close a major treatment gap.
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
What Clinicians Need to Know About Postpartum Psychosis
2
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
3
Brain Trust: Therapeutic Drug Monitoring and Adherence in Schizophrenia, With Jonathan M. Meyer, MD
4
AI as a Task-Replacing Tool for Psychiatric Care: A Conversation With Christoph Correll, MD
5